Showing 1 - 4 of 4 Lymphoma
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy

Status: Open Not Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them una ... Read more >

A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)

Status: Open Not Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stoppi ... Read more >

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Status: Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibod ... Read more >

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator:

Phone:

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >

Live Chat Available